• Clinicians view new Alzheimer's drug with guarded optimism

    1 month ago - By Healio

    This year, Biogen is expected to submit a Biologics License Application to the FDA for its anti-amyloid antibody, aducanumab. If approved, it will be the first new drug available to patients with Alzheimer's disease in 16 years.
    Administered intravenously once a month, aducanumab clears some of the plaque materials that may cause cell death and tissue loss in the brain caused by Alzheimer's disease, according to Barry Reisberg, MD, one of the clinical investigators who developed the Alzheimer's drug memantine, which was approved back in 2003.
    Although it is not curative, aducanumab
    Read more ...